This approach has been effective in a few malignancies including metastatic prostate cancer where the provision of 177Lu-PSMA-617 in men with advanced PSMA-avid metastatic castration-resistant prostate cancer has been shown to improve progression-free survival and overall survival compared to standard care (34). The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.